U.S. – Talk Bio

Independent expert group to review HPV vaccine evidence after US recommendation change

3 weeks ago talkbio0Tagged ACIP, CDC, Centers for Disease Control and Prevention (U.S.), Childhood, CIDRAP, disbanded, Gardasil, HPV vaccine, Immunization Schedule, independent review, recommendation change, single-dose schedule, U.S., Vaccine Integrity Project

HPV vaccine; Vaccine Integrity Project; independent review; CDC recommendation change; single-dose schedule; ACIP disbanded; CIDRAP; Robert F. Kennedy Jr.; US childhood immunization schedule; Gardasil

AstraZeneca appoints Rick R. Suarez to lead U.S. BioPharmaceuticals business and $50B investment drive

3 weeks ago talkbio0Tagged AstraZeneca, Biological Factors, Head of US, Investments, President brand of dental material, Rick R. Suarez, Surgical aspects, U.S., Virginia manufacturing facility, Wilmington Delaware

AstraZeneca; Rick R. Suarez; US President; Head of US BioPharmaceuticals Business Unit; $50 billion US investment; Virginia manufacturing facility; US operations; biopharmaceuticals; revenue goal 2030; Wilmington Delaware

Novo Nordisk Launches Wegovy Pill in the US with Broad Availability

3 weeks ago talkbio0Tagged Glucagon-Like Peptide 1, January 2026, Novo Nordisk, Oral cavity, U.S., Wegovy pill, Weight Loss

Novo Nordisk; Wegovy pill; US launch; January 2026; oral GLP-1; weight loss

US Commits $480-487 Million in Health Funding to Ivory Coast Under ‘America First’ Health Strategy

4 weeks ago talkbio0Tagged Americas, COAST, deals, Funding, global health security, Health, HIV, Ivory, Malaria, Tuberculosis, U.S.

US Ivory Coast health agreement; America First health deals; $487 million funding; HIV malaria tuberculosis; global health security

White House unveils nine new “most-favored-nation” drug pricing deals

1 month ago talkbio0Tagged drug price, eli lilly, Health Policy, MFN, Most-Favored-Nation, Nordisk, Ozempic, pharmaceutical manufacturers, prescription drug costs, Trump administration, U.S., Wegovy, White House

most-favored-nation pricing; MFN; drug pricing; White House; Trump administration; pharmaceutical manufacturers; Ozempic; Wegovy; Eli Lilly; Novo Nordisk; prescription drug costs; US healthcare policy

Recent Developments in Medical Affairs Reputation and Hemophilia A Management in the US (2025)

2 months ago talkbio0Tagged Acquired (qualifier value), Centers for Disease Control and Prevention (U.S.), federal funding, gene therapy, Health Policy, Hemophilia A, Hemophilia A Pipeline, Hemophilia Treatment Centers, HRSA, Medical Affairs, Programs - Publication Format, public health policy, reputation, U.S.

Medical Affairs; Reputation; Hemophilia A; US; 2025; Gene Therapy; Public Health Policies; Hemophilia Treatment Centers; 340B Program; Federal Funding; Acquired Hemophilia A Pipeline; Healthcare Policy; CDC; HRSA

AstraZeneca Onshores Rare Disease Portfolio as Part of $50B US Investment Pledge

2 months ago talkbio0Tagged AstraZeneca, expansion, Infrequent, Investments, Maryland (geographic location), onshoring, pledge, portfolio, R&D, U.S., Virginia facility

AstraZeneca; rare disease portfolio; onshoring; US investment; biomanufacturing; $50 billion pledge; Virginia facility; Maryland investment; R&D expansion

US-Backed Group Reports Success with New Tuberculosis Treatment in Phase 2 Study

2 months ago talkbio0Tagged Clinical Trials, drug-resistant TB, linezolid, Phase 2 clinical trial, pretomanid, sorfequiline, SPaL, TB Alliance, Treatment Protocols, Tuberculosis, U.S., ultra-short regimen

tuberculosis; TB Alliance; Phase 2 clinical trial; sorfequiline; SPaL regimen; pretomanid; linezolid; drug-resistant TB; ultra-short regimen; US support; clinical trial results

Pharma Investment Surge in US Manufacturing Creates Major Opportunities for CDMOs

3 months ago talkbio0Tagged Advanced therapies, alpha 1-antitrypsin, Biological Factors, capital investment, CDMOs, eli lilly, Growth, Johnson & Johnson, Market, pharmaceutical manufacturing, production, supply chain, U.S.

US pharmaceutical manufacturing; CDMOs; capital investment; Johnson & Johnson; Eli Lilly; biologics; API production; supply chain; advanced therapies; market growth

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact

3 months ago talkbio0Tagged Clearmind Medicine, Clinical Trials, governmental engagement, Mary-Elizabeth, mental health, partnerships, psychedelic medicine, regulatory advocacy, U.S.

Clearmind Medicine; Mary-Elizabeth Gifford; Chief of Global Impact; psychedelic medicine; US partnerships; governmental engagement; regulatory advocacy; biotech company; clinical trials; mental health